Inhibikase Therapeutics, Inc.

Biotechnology • Healthcare • Atlanta, GA, United States • IKT (NCM)

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is based in Atlanta, Georgia.

678 392 3419 3350 Riverwood Parkway SE, Atlanta, GA 30339, United States

Stock Performance (90 Days)

Data through Dec 29, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat

MarketBeat • Dec 27

Inhibikase Therapeutics (IKT): HC Wainwright & Co. Issues 'Buy' Rating | IKT Stock News - GuruFocus

GuruFocus • Dec 26

H.C. Wainwright assumes coverage on Inhibikase stock with Buy rating - Investing.com

Investing.com • Dec 26

Inhibikase Therapeutics Announces $93.6 Million Stock Offering - MSN

MSN • Dec 24

Institutions own 29% of Inhibikase Therapeutics, Inc. (NASDAQ:IKT) shares but individual investors control 41% of the company - Yahoo Finance

Yahoo Finance • Dec 8

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Inhibikase Therapeutics, Inc. had layoffs?

No layoff events have been recorded for Inhibikase Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does Inhibikase Therapeutics, Inc. have?

Inhibikase Therapeutics, Inc. has approximately 15 employees.

What industry is Inhibikase Therapeutics, Inc. in?

Inhibikase Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.

Is Inhibikase Therapeutics, Inc. a publicly traded company?

Yes, Inhibikase Therapeutics, Inc. is publicly traded under the ticker symbol IKT on the NCM. The company has a market capitalization of approximately $0.24 billion.

Where is Inhibikase Therapeutics, Inc. headquartered?

Inhibikase Therapeutics, Inc. is headquartered in Atlanta, GA, United States at 3350 Riverwood Parkway SE, Atlanta, GA 30339, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.